Progress and challenges in the treatment of small cell lung cancer

Alfredo Tartarone, Pasqualina Giordano, Rosa Lerose, Maria Grazia Rodriquenz, Raffaele Conca, Michele Aieta

Research output: Contribution to journalReview articlepeer-review


Small cell lung cancer (SCLC) is a very aggressive malignancy characterized by high cellular proliferation and early metastatic spread. In fact, although SCLC is a chemosensitive and radiosensitive disease, the initial responsiveness to chemotherapy is usually followed by development of resistance and the prognosis remains poor with a median survival of less than 12 months in patients with extensive disease (ED-SCLC). Furthermore, no significant progress has been made over the last years, with no newly approved drug. For all these reasons, SCLC represents for the oncologists a major challenge and an exciting field of clinical research. In this review, we analyze the most promising advances in development for SCLC with a special focus on antiangiogenic treatments, immunotherapy, novel chemotherapeutic and targeted agents.

Original languageEnglish
Article number110
JournalMedical Oncology
Issue number6
Publication statusPublished - Jun 1 2017


  • Antiangiogenic therapy
  • Bevacizumab
  • Immune checkpoint inhibitors
  • Immunotherapy
  • Rovalpituzumab tesirine (Rova-T)
  • Small cell lung cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Progress and challenges in the treatment of small cell lung cancer'. Together they form a unique fingerprint.

Cite this